Prostanoid-dependent abdominal aortic aneurysm formation

前列腺素依赖性腹主动脉瘤形成

• 批准号: 7413673
• 负责人: Charles David Loftin
• 金额: $ 29.08万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7413673
• 关键词: Abdomen; Abdominal Aortic Aneurysm; Angiotensin II; Animal Disease Models; Animal Model; Anti-Inflammatory Agents; Anti-inflammatory; Aorta; Aortic Aneurysm; Apoptosis; Arachidonic Acids; Attenuated; Binding; Biological; Blood Vessels; Cardiovascular Diseases; Cardiovascular system; Cell Adhesion Molecules; Chronic; Data; Development; Dinoprostone; Disease; Disease regression; EP4 receptor; Effectiveness; Elderly; Event; Genetic; Health; Human; Incidence; Infiltration; Inflammation; Inflammatory; Inflammatory Response; Infusion procedures; Life; Matrix Metalloproteinases; Mediating; Messenger RNA; Metabolic; Modeling; Mus; Operative Surgical Procedures; Pathology; Pharmaceutical Preparations; Pharmacological Treatment; Play; Population; Prostaglandin E Receptor; Prostaglandin H2; Prostaglandin-Endoperoxide Synthase; Prostaglandins; Protein Isoforms; Reporting; Research Personnel; Role; Rupture; Severities; Smooth Muscle Myocytes; Staging; Stimulus; Testing; Thinking; Thromboxane A2; Thromboxane Receptor; Tissues; Wild Type Mouse; Work; abdominal aorta; aging population; base; celecoxib; chemokine; cyclooxygenase 1; cyclooxygenase 2; human WFDC2 protein; inhibitor/antagonist; insight; interest; macrophage; male; monocyte; novel therapeutics; programs; receptor; response

DESCRIPTION (provided by applicant): Our recent report together with our preliminary studies show that genetic or pharmacological inactivation of cyclooxygenase-2 (COX-2) reduces the incidence and severity of AAAs in mice chronically infused with angiotensin II (Angll). Furthermore, significant COX-2 expression is increased in AAAs as compared to the uninvolved aorta. Our preliminary studies also show that the expression of the PGE2 receptor EP4 is significantly increased in aneurysmal tissue. However, the role of the prostanoid receptors in AAA formation is not clearly defined. The long-term objectives of this proposal are to elucidate mechanisms by which prostanoids contribute to AAAs. We propose the hypothesis that COX-2 participates in all stages of Angll- induced AAA development through preferential synthesis of PGE2 and TXA2 which specifically activate EP4 and TP receptors, respectively. This hypothesis is based on previous observations that a) Explant cultures from human AAAs express significant levels of COX-2. b) PGE2 contributes to vascular pathology by increasing expression and/or activation of matrix metalloproteinases and inducing smooth muscle cell apoptosis. c) TXA2 increases adhesion molecule expression and contributes to influx of macrophages in the vessel wall. Therefore, we propose the following specific aims: 1) Determine the role of COX-2 at multiple stages of AAA formation. These studies will use mice genetically deficient in COX-2 as well as the COX-2- specific inhibitor, celecoxib. 2) Determine the effect of genetic deficiency of the prostanoid receptors, EP4 and TP, on AAA formation. These studies will provide a mechanistic view of the role of COX-2-dependent prostanoids, and will provide insight into the development of novel therapeutics for AAAs. The objectives of the proposed studies are to identify new treatments for abdominal aortic aneurysms (AAAs). AAAs are a life-threatening disease which afflict approximately 5% of the male population over the age of 65, and once the disease has formed, there is an increased chance for rupture of the aorta, an event which most people do not survive. The cause of aortic aneurysms in humans is not known but is thought to involve inflammation within the wall of the aorta. Therefore, we will use an animal model of this disease to determine the mechanisms by which this disease occurs in humans. These studies are important as they will help identify non-surgical treatments for this disease in humans.

描述(申请人提供)：我们最近的报告和我们的初步研究表明，环氧合酶-2(COX-2)的遗传或药物失活降低了长期注射血管紧张素II(Ang11)的小鼠AAA的发生率和严重程度。此外，与未受累的主动脉相比，腹主动脉曲张中COX-2的表达显著增加。我们的初步研究还表明，PGE2受体Ep4在动脉瘤组织中的表达显著增加。然而，前列腺素受体在AAA形成中的作用尚不清楚。这项建议的长期目标是阐明前列腺素对AAA的作用机制。我们提出的假设是，COX-2通过优先合成PGE2和TXA2来参与Ang11诱导的AAA发展的所有阶段，PGE2和TXA2分别特异性地激活EP4和TP受体。这一假设是基于以前的观察结果，即a)人AAA的外植体培养表达显著水平的COX-2。2)前列腺素E_2通过增加基质金属蛋白酶的表达和/或激活，诱导血管细胞凋亡，参与血管病理过程。C)TXA2增加黏附分子的表达，促进巨噬细胞进入血管壁。因此，我们提出了以下具体目标：1)确定COX-2在AAA形成的多个阶段中的作用。这些研究将使用COX-2基因缺陷的小鼠以及COX-2特异性抑制剂塞来昔布。2)确定前列腺素受体EP4和TP的遗传缺陷对AAA形成的影响。这些研究将提供COX-2依赖的前列腺素作用的机制观点，并将为AAA的新疗法的发展提供洞察力。拟议研究的目的是确定腹主动脉瘤(AAA)的新治疗方法。AAAS是一种危及生命的疾病，65岁以上的男性人口中约有5%受到这种疾病的困扰，一旦形成这种疾病，发生主动脉破裂的可能性就会增加，而大多数人都无法幸存下来。人类主动脉瘤的病因尚不清楚，但被认为与主动脉壁内的炎症有关。因此，我们将使用这种疾病的动物模型来确定这种疾病在人类中发生的机制。这些研究很重要，因为它们将有助于确定人类这种疾病的非手术治疗方法。